BROADWOOD PARTNERS LP 13D and 13G filings for Lineage Cell Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-01-28 8:07 pm Purchase |
2025-01-27 | 13D | Lineage Cell Therapeutics, Inc. LCTX |
BROADWOOD PARTNERS LP | 57,848,357 24.500% |
15,789,474 (+37.54%) |
Filing |
| 2024-11-21 8:05 pm Purchase |
2024-11-19 | 13D | Lineage Cell Therapeutics, Inc. LCTX |
BROADWOOD PARTNERS LP | 42,058,883 19.100% |
75,000 (+0.18%) |
Filing |
| 2024-02-08 6:57 pm Purchase |
2024-02-06 | 13D | Lineage Cell Therapeutics, Inc. LCTX |
BROADWOOD PARTNERS LP | 41,983,883 22.200% |
6,756,610 (+19.18%) |
Filing |
| 2022-03-25 5:23 pm Purchase |
2022-03-10 | 13D | Lineage Cell Therapeutics, Inc. LCTX |
BROADWOOD PARTNERS LP | 35,227,273 20.700% |
980,106 (+2.86%) |
Filing |
| 2021-03-16 5:04 pm Purchase |
2021-03-11 | 13D | Lineage Cell Therapeutics, Inc. LCTX |
BROADWOOD PARTNERS LP | 34,247,167 21.200% |
34,247,167 (New Position) |
Filing |